Medtech Marketing Strategy: Why Clinical Proof Alone Won’t Grow Your Market

Medtech marketing strategy is the commercial framework that connects a medical technology product to the clinicians, procurement teams, and patients who need it. Done well, it aligns clinical evidence, market access, and demand generation into a coherent plan that drives adoption, not just awareness. Done poorly, it produces expensive brochures that gather dust in hospital waiting rooms.

The challenge in medtech is that the product development cycle is long, the regulatory environment is demanding, and the sales motion is complex. By the time most medtech companies get to market, they have exhausted their appetite for risk. Marketing becomes an afterthought, and the commercial team is left trying to build demand with tools that were never designed for this category.

Why Most Medtech Companies Start Commercial Planning Too Late

I have worked with businesses across 30 industries, and medtech has one of the most consistent patterns of commercial underinvestment relative to product investment. Companies spend years and tens of millions developing a device or diagnostic, then allocate a fraction of that to figuring out how to sell it. The result is a technically excellent product with a poorly constructed commercial story and no real plan for reaching the people who need to buy it.

Forrester has documented this problem in detail. Their research on healthcare go-to-market struggles in devices and diagnostics highlights how medtech companies routinely underestimate the complexity of the buying process and overestimate the power of clinical data to do commercial work on its own.

The assumption tends to be: if the clinical evidence is strong, the product will sell itself. That is almost never true. Clinical evidence gets you in the room. It does not close the deal, and it certainly does not build a market.

If you are thinking about go-to-market strategy more broadly, the frameworks and principles covered in our Go-To-Market and Growth Strategy hub apply across categories, including medtech, where the stakes for getting the launch right are particularly high.

What Makes Medtech Marketing Different From Other B2B Categories

Medtech sits in an unusual commercial position. It has the technical complexity of enterprise software, the regulatory constraints of pharmaceuticals, the emotional weight of healthcare, and the procurement dynamics of public sector purchasing. No single B2B marketing playbook handles all of that cleanly.

The buying committee is typically large and heterogeneous. A clinical champion may love the product. A procurement manager is focused on total cost of ownership. A finance director is thinking about capital expenditure cycles. An infection control lead has questions about implementation. A hospital CEO wants to know about patient outcomes data and reputational risk. Each of these stakeholders needs a different conversation, and most medtech marketing addresses only one or two of them.

There is also the question of market maturity. Some medtech products enter categories where the clinical problem is well understood and the market is established. Others are genuinely pioneering, entering categories where the first commercial challenge is not “why choose us” but “why does this problem matter enough to invest in solving it.” These are fundamentally different marketing problems, and they require different strategies.

BCG’s work on biopharma product launch strategy is instructive here, even for device companies. The principle that launch decisions made in the first six to twelve months tend to define the commercial trajectory of a product for years holds just as true in medtech as it does in pharma. Getting the strategy right early is not a luxury. It is a commercial imperative.

The Problem With Relying on Performance Marketing in Medtech

Earlier in my career, I was heavily focused on lower-funnel performance. I believed that if you could capture intent at the right moment, the commercial case was made. Over time, managing hundreds of millions in ad spend across industries, I became much more sceptical of that view. A significant portion of what performance marketing gets credit for was going to happen anyway. You are often capturing demand that already existed, not creating new demand.

In medtech, this problem is acute. If a surgeon is already looking for a solution to a specific clinical problem, capturing that intent is relatively straightforward. But the bigger commercial opportunity, especially for innovative or pioneering products, is reaching the clinicians and procurement teams who have not yet recognised the problem as one worth solving. Performance marketing does not do that work. It finds people who are already looking. It does not create the conditions that make people start looking.

Think of it like a clothes shop. Someone who tries something on is far more likely to buy than someone who walks past the window. Performance marketing is the window display. It catches the eye of people who are already on the high street, already in a buying mindset. Market shaping is the work of getting people onto the high street in the first place. In medtech, that distinction matters enormously, because the high street can be very sparsely populated.

What Market Shaping Actually Means in a Medtech Context

Market shaping is the commercial work of changing how a problem is understood before you sell the solution. In medtech, this often means investing in clinical education, health economics research, advocacy, and thought leadership that reframes a clinical issue as one that has a better solution than the current standard of care.

I spent time working with a business that was bringing a genuinely innovative diagnostic to market. The clinical evidence was strong. The problem was that the clinical community had been managing the condition in a particular way for decades and had not identified their current approach as suboptimal. The commercial challenge was not “why choose our diagnostic” but “why should you be diagnosing this differently at all.” That is a market shaping problem, and no amount of Google Ads spend was going to solve it.

Market shaping in medtech typically involves a combination of peer-reviewed publication strategy, key opinion leader engagement, health economics and outcomes research, clinical guideline influence, and conference presence. These are slow, expensive, and difficult to attribute. They are also often the most commercially valuable investments a medtech company can make, because they create the conditions in which your commercial team can actually have productive conversations.

BCG’s broader work on commercial transformation and go-to-market strategy makes a related point: companies that win in complex markets tend to invest in changing the commercial environment, not just responding to it. In medtech, that means investing upstream, before the buying process begins.

Building a Medtech Marketing Strategy That Actually Works

A functional medtech marketing strategy has five components that need to work together. Most medtech companies have two or three of them. The gaps are usually where the commercial problems live.

1. A clear market definition and segmentation model

This sounds obvious. It rarely gets done properly. Medtech companies tend to define their market by indication or device category, which tells you who might theoretically benefit from the product. That is not the same as defining your addressable market, your priority segments, and your sequencing logic for how you will move through those segments over time.

Good segmentation in medtech considers clinical setting, institutional type, payer environment, existing pathway, and the specific profile of the clinical champion most likely to drive adoption. It also considers geography, because reimbursement, procurement, and clinical culture vary significantly across markets, even within a single country.

2. A stakeholder mapping and messaging architecture

Every member of the buying committee needs a version of your commercial story that is relevant to their specific concerns. The clinical champion needs evidence of efficacy and safety. The procurement lead needs total cost of ownership data. The finance director needs a capital expenditure model and a payback period. The C-suite needs outcomes data and reputational upside.

Most medtech companies have one version of their story, written for clinicians, and then wonder why procurement is slow or why the CFO keeps asking questions that the clinical team cannot answer. The messaging architecture needs to be built before the sales team goes to market, not improvised during the sales process.

3. A content and education strategy tied to the clinical pathway

Content in medtech is not blog posts and social media updates. It is clinical white papers, health economics models, case studies from early adopter sites, training materials, and reimbursement guides. The content strategy needs to map to the stages of the clinical and commercial decision-making process, not to a generic content marketing framework borrowed from SaaS.

That said, digital content matters more in medtech than it did ten years ago. Clinicians research products online. Procurement teams look for independent validation. A medtech company with no meaningful digital presence is leaving commercial ground unclaimed. The question is not whether to invest in digital content, but how to make it clinically credible and commercially useful at the same time.

4. A demand generation model that matches your market maturity

If you are in an established category where the clinical problem is well understood and the buying process is familiar, demand generation can lean more heavily on performance channels, account-based marketing, and sales enablement. If you are pioneering a new category or reshaping an existing one, demand generation needs to include significant investment in market shaping activities that will not show up cleanly in your attribution model.

The mistake I see repeatedly is applying an established-category demand generation model to a pioneering product. You end up spending money capturing a tiny pool of existing intent and wondering why pipeline is not building. The answer is usually that you have not yet created enough awareness of the problem to generate meaningful intent in the first place.

5. A measurement framework that reflects commercial reality

Medtech sales cycles are long. A deal that closes in month eighteen may have been influenced by a conference presentation in month three, a white paper in month six, and a site visit in month twelve. Attributing that deal entirely to the last touchpoint before contract signature is analytically dishonest and commercially misleading.

I have judged the Effie Awards, which are specifically focused on marketing effectiveness, and one of the most consistent findings across winning entries is that effective marketing tends to work across multiple timeframes simultaneously. Short-term activation and long-term brand building are not competing priorities. They are complementary investments. In medtech, the long-term investment in reputation, relationships, and clinical credibility is often the thing that makes the short-term commercial activity possible at all.

The Role of Digital Channels in Medtech Go-To-Market

Digital channels in medtech are underused in some areas and misused in others. The underuse tends to be in organic search and content, where medtech companies either produce nothing or produce content that is so heavily qualified for regulatory reasons that it communicates nothing useful. The misuse tends to be in paid social, where medtech companies run awareness campaigns that reach the wrong audiences with messages that do not land.

LinkedIn is genuinely useful in medtech because the targeting capabilities allow you to reach specific clinical roles, institutional types, and geographies. It is not a replacement for direct clinical engagement, but it can support thought leadership, drive traffic to substantive content, and keep your brand visible to stakeholders who are not yet in an active buying process.

Search is valuable for capturing existing intent, particularly around specific device categories, clinical conditions, and reimbursement questions. If clinicians and procurement teams are searching for information about your category, you want to be the source they find. That requires investment in SEO and in the kind of substantive, credible content that ranks well and earns trust when people arrive.

Tools that help you understand search demand and content gaps can be genuinely useful here. Platforms like those covered in Semrush’s overview of growth tools can help medtech marketing teams identify where organic search opportunity exists in their category and what questions their target audiences are actually asking.

Where Medtech Marketing Most Often Goes Wrong

After working across a range of healthcare and medtech clients, the failure patterns are remarkably consistent. They are worth naming directly.

The first is treating marketing as a communication function rather than a commercial function. Marketing in medtech is often given the job of producing materials and running events, but is not involved in pricing strategy, market access planning, or commercial model design. That is a structural mistake. Marketing should be in the room when those decisions are being made, because they shape what is commercially possible.

The second is building the commercial story around the product rather than around the clinical problem. Clinicians are not looking for a device. They are looking for a better way to solve a specific clinical problem for a specific patient population. The commercial story needs to start with the problem, not the product. This sounds simple. It is surprisingly rare in practice.

The third is underinvesting in health economics. In most healthcare systems, the question of whether a product delivers value relative to its cost is as important as whether it delivers clinical benefit. A medtech company without a credible health economics story will struggle in any system where procurement is involved, which is almost every system. This is not a marketing afterthought. It is a core commercial asset.

The fourth is conflating product quality with commercial strategy. I have seen genuinely excellent products fail commercially because the company assumed that clinical superiority would translate into market share without the commercial infrastructure to support it. The best product does not always win. The product with the best commercial strategy usually does.

This connects to something I believe about marketing more broadly. If a company genuinely delighted its customers at every touchpoint, that alone would drive significant growth. But marketing is often being asked to compensate for more fundamental commercial problems: a product that is not differentiated enough, a pricing model that does not fit the market, a sales team that is not equipped to have the right conversations. In medtech, those problems are common, and no marketing strategy will fix them on its own.

For more frameworks on building commercial strategies that address root causes rather than symptoms, the Go-To-Market and Growth Strategy hub covers the principles that apply across complex B2B categories, including the ones where medtech companies most often struggle.

Practical Principles for Medtech Marketers

If you are building or rebuilding a medtech marketing strategy, a few principles tend to hold regardless of category, geography, or commercial stage.

Start with the buying committee, not the product. Map every stakeholder who has a meaningful role in the purchase decision, understand their specific concerns, and build your commercial story from there. The clinical champion is usually the easiest person to convince. They are rarely the hardest person to convince. Build for the hardest conversations first.

Invest in market shaping before you need it. The work of changing how a clinical problem is understood takes time. If you start that work at launch, you are already behind. The companies that do this well start building clinical credibility and thought leadership before the product is commercially available, so that by the time they go to market, the conditions for adoption already exist.

Build a measurement framework that reflects the actual sales cycle. A medtech deal that takes eighteen months to close is influenced by dozens of touchpoints. Measure leading indicators, clinical engagement, conference attendance, content consumption, site visit requests, alongside lagging indicators like pipeline and revenue. Do not let the difficulty of attribution push you toward measuring only what is easy to measure.

Treat health economics as a marketing asset, not a regulatory requirement. A well-constructed health economics model is one of the most powerful commercial tools a medtech company can have. It answers the questions that procurement and finance will ask before the clinical team even gets to present. Build it early, update it with real-world data, and make it accessible to your commercial team.

And finally, be honest about what marketing can and cannot fix. Marketing can build awareness, generate demand, support the sales process, and shape how your category is understood. It cannot fix a product that is not differentiated, a pricing model that does not fit the market, or a sales team that is not equipped to execute. If those problems exist, they need to be addressed alongside the marketing strategy, not instead of it.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions